Lirilumab (IPH2101, 1-7F9)
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for Lirilumab (IPH2101, 1-7F9), covering 2014-02-28 to 2014-02-28. Get the full timeline:
Most recent: Clinical Trial Update: A Safety and Tolerability Extension Trial Assessing Repeated Dosing of Anti-KIR (1-7F9) Human Monoclonal Antibody in Patients With Acute Myeloid Leukaemia [Phase 1]